These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy. Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693 [TBL] [Abstract][Full Text] [Related]
27. Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy. Liesenfeld L; Kron M; Gschwend JE; Herkommer K J Urol; 2017 Jan; 197(1):143-148. PubMed ID: 27418452 [TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial. Wiegel T; Bartkowiak D; Bottke D; Thamm R; Hinke A; Stöckle M; Rübe C; Semjonow A; Wirth M; Störkel S; Golz R; Engenhart-Cabillic R; Hofmann R; Feldmann HJ; Kälble T; Siegmann A; Hinkelbein W; Steiner U; Miller K Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):288-94. PubMed ID: 25445556 [TBL] [Abstract][Full Text] [Related]
29. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy. Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132 [TBL] [Abstract][Full Text] [Related]
30. Neoplastic and antineoplastic effects of beta-carotene on colorectal adenoma recurrence: results of a randomized trial. Baron JA; Cole BF; Mott L; Haile R; Grau M; Church TR; Beck GJ; Greenberg ER J Natl Cancer Inst; 2003 May; 95(10):717-22. PubMed ID: 12759389 [TBL] [Abstract][Full Text] [Related]
31. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. Michalski JM; Moughan J; Purdy J; Bosch W; Bruner DW; Bahary JP; Lau H; Duclos M; Parliament M; Morton G; Hamstra D; Seider M; Lock MI; Patel M; Gay H; Vigneault E; Winter K; Sandler H JAMA Oncol; 2018 Jun; 4(6):e180039. PubMed ID: 29543933 [TBL] [Abstract][Full Text] [Related]
32. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer. Beard CJ; Chen MH; Cote K; Loffredo M; Renshaw AA; Hurwitz M; D'Amico AV Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):19-24. PubMed ID: 14697416 [TBL] [Abstract][Full Text] [Related]
33. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients. Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488 [TBL] [Abstract][Full Text] [Related]
34. Natural history of 'second' biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study. Tumati V; Jackson WC; Abugharib AE; Raj G; Roehrborn C; Lotan Y; Courtney K; Bagrodia A; Gahan JC; Zumsteg ZS; Folkert MR; Laine AM; Hannan R; Spratt DE; Desai NB BJU Int; 2018 Mar; 121(3):365-372. PubMed ID: 28581200 [TBL] [Abstract][Full Text] [Related]
35. Vitamins C and E and beta carotene supplementation and cancer risk: a randomized controlled trial. Lin J; Cook NR; Albert C; Zaharris E; Gaziano JM; Van Denburgh M; Buring JE; Manson JE J Natl Cancer Inst; 2009 Jan; 101(1):14-23. PubMed ID: 19116389 [TBL] [Abstract][Full Text] [Related]
36. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter? Hsu CC; Paciorek AT; Cooperberg MR; Roach M; Hsu IC; Carroll PR BJU Int; 2015 Nov; 116(5):713-20. PubMed ID: 25600860 [TBL] [Abstract][Full Text] [Related]
37. Long-term cancer control after radical prostatectomy and bilateral pelvic lymph node dissection for pT3bN0M0 prostate cancer in the prostate-specific antigen era. Fairey AS; Daneshmand S; Skinner EC; Schuckman A; Cai J; Lieskovsky G Urol Oncol; 2014 Feb; 32(2):85-91. PubMed ID: 24183191 [TBL] [Abstract][Full Text] [Related]
38. Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients. Romesser PB; Pei X; Shi W; Zhang Z; Kollmeier M; McBride SM; Zelefsky MJ Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):59-67. PubMed ID: 29254782 [TBL] [Abstract][Full Text] [Related]
39. Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer. Stroup SP; Moreira DM; Chen Z; Howard L; Berger JH; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Kane CJ; Freedland SJ J Urol; 2017 Dec; 198(6):1309-1315. PubMed ID: 28709888 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of biochemical recurrence-free survival after radical prostatectomy by cancer of the prostate risk assessment post-surgical (CAPRA-S) score. Aktas BK; Ozden C; Bulut S; Tagci S; Erbay G; Gokkaya CS; Baykam MM; Memis A Asian Pac J Cancer Prev; 2015; 16(6):2527-30. PubMed ID: 25824791 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]